Patent · US Active

Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases

US9545450B2 · kind B2 · utility

14Cited by
1References
14Claims
0Family size

Assignee

Inventor

Key dates

Filing dateMay 25, 2012
Grant dateJan 17, 2017
Priority date
Expiry dateJul 11, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/50
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Described herein are methods of making targeting peptides conjugated to recombinant lysosomal enzymes by modifying the amino (N)-terminus and one or more lysine residues on recombinant human lysosomal enzymes using a first crosslinking agent to give rise to first crosslinking agent modified recombinant human lysosomal enzymes, modifying the first amino acid within a short linker at the amino (N)-terminus on a variant IGF-2 peptide using a second crosslinking agent to give rise to a second crosslinking agent modified variant IGF-2 peptide, and then conjugating the first crosslinking agent modified recombinant human lysosomal enzyme to the second crosslinking agent modified variant IGF-2 peptide containing a short linker. Also described herein are conjugates synthesized characterized as having higher affinities for the IGF2/CI-MPR receptor and cellular uptake using the methods disclosed herein. Also described herein are treatment methods using the disclosed conjugates.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.